Real-World Evidence Highlights Broader Benefits of Omalizumab for Food Allergy Management

Key Clinical Summary

• A narrative review of real-world studies found that omalizumab may provide benefits beyond reducing allergic reactions, including improved dietary flexibility, quality of life, and confidence in managing food allergies.
• Observational evidence suggests that omalizumab may be effective and well tolerated in patients with complex food allergies, multiple allergic conditions, and elevated immunoglobulin E (IgE) levels, although evidence supporting use outside approved dosing parameters remains limited.
• Emerging research suggests that food allergy-specific dosing strategies may improve treatment individualization, highlighting opportunities for further investigation into dosing optimization and long-term outcomes.

Real-world evidence suggests that omalizumab may provide broader clinical and quality-of-life benefits for patients with immunoglobulin E (IgE)-mediated food allergies than those typically captured in randomized clinical trials, according to a narrative review examining observational studies published between 2006 and 2026.

The review, Real-life lessons on omalizumab and food allergy: The potential for unexplored outcomes, evaluated the treatment's effects on allergic reaction thresholds, dietary restrictions, psychosocial well-being, and outcomes among patients with complex allergic conditions. The findings highlight opportunities to individualize treatment while identifying evidence gaps relevant to clinical and managed care decision-making.

Real-World Research Expands Understanding of Omalizumab Benefits

In 2024, the US Food and Drug Administration approved omalizumab (Xolair) to reduce allergic reactions, including anaphylaxis, that may occur following accidental exposure to food allergens in eligible patients aged 1 year or older.

Although clinical trials have established the treatment's ability to increase reaction thresholds, the review authors noted that traditional efficacy measures may not fully capture the impact of treatment on patients' daily lives.

Researchers examined observational cohorts, case series, and case reports evaluating omalizumab in patients with food allergies, including individuals with multiple allergic conditions and those typically excluded from randomized trials.

The review identified several potential benefits beyond protection against accidental allergen exposure, including greater dietary flexibility, reduced anxiety, and improved food allergy-related quality of life.

Observational studies also described patients who successfully reintroduced previously avoided foods while receiving treatment. However, dietary expansion requires individualized clinical assessment and should not be interpreted as evidence that omalizumab eliminates the need for allergen avoidance or emergency preparedness.

Treatment Benefits Extend to Patients With Complex Allergic Conditions

The review highlighted evidence supporting omalizumab use among patients with multiple food allergies and coexisting allergic diseases.

In an early prospective study involving 22 patients aged 4 to 66 years with persistent asthma and food allergies, omalizumab treatment was associated with improvements in allergic symptoms, including food-induced asthma, dermatitis, and anaphylaxis. Several patients also demonstrated increased tolerance to previously reactive foods.

Another case series involving 8 children with severe allergic asthma and food allergies found improvements in asthma control and food tolerance during treatment lasting up to 2 years. Two patients successfully underwent milk oral immunotherapy while receiving omalizumab, and no serious adverse events were reported.

The review also examined outcomes among patients with food allergies and eosinophilic esophagitis. Although some patients experienced improvements in allergic symptoms and food tolerance, esophageal inflammation remained unchanged, suggesting that treatment benefits may differ across allergic conditions.

These findings indicate that omalizumab may provide benefits for patients with overlapping allergic conditions, although larger controlled studies are needed to establish its effectiveness across specific patient populations.

Elevated IgE Levels Raise Questions About Dosing Strategies

The researchers also examined omalizumab use among patients with exceptionally high baseline IgE levels, including those outside approved dosing parameters.

One case series followed 7 children with asthma and multiple food allergies who received omalizumab at monthly doses ranging from 600 to 1200 mg.

The patients had a mean baseline total IgE level of 2158 kU/L, with individual values ranging from 1699 to 3307 kU/L.

All patients achieved asthma control and complete desensitization during treatment, with no adverse events reported.

Although encouraging, these findings were based on a small observational sample and do not establish the safety or effectiveness of dosing outside approved recommendations.

Additional research suggests that food allergy treatment may require dosing approaches different from those traditionally used for allergic asthma.

In a Canadian cohort of 181 children and young adults receiving omalizumab alongside multifood oral immunotherapy, researchers found that body weight was a stronger predictor of changes in allergic reaction thresholds than baseline total IgE levels.

Similar findings were reported in the OSAFA observational cohort, suggesting that body weight-based dosing may warrant further investigation in food allergy management.

The review authors emphasized that optimal dosing, treatment duration, and discontinuation strategies remain uncertain.

Implications for Managed Care

The findings highlight the importance of evaluating omalizumab's potential benefits beyond conventional clinical efficacy measures.

For managed care organizations, outcomes such as dietary flexibility, reduced anxiety, and improved quality of life may provide additional context when assessing the treatment's overall value.

The review also suggests that patients with multiple food allergies, recurrent severe reactions, or substantial psychosocial burden may have particularly important unmet treatment needs.

However, the available observational evidence does not establish whether these benefits translate into reduced emergency department utilization, fewer hospitalizations, or lower overall health care expenditures.

The possibility of individualized dosing also introduces considerations for coverage policies and treatment optimization. Although emerging research suggests that alternative dosing strategies may be appropriate for certain patients, additional evidence is necessary before these approaches can be incorporated into routine practice.

The authors acknowledged several limitations, including heterogeneous study designs, small patient populations, variable follow-up periods, and inconsistent outcome definitions. The narrative review also did not include a formal risk-of-bias assessment.

Conclusion

Real-world evidence suggests that omalizumab may provide multidimensional benefits for patients with IgE-mediated food allergies, including increased reaction thresholds, improved dietary flexibility, and reduced psychosocial burden.

The findings also identify potential opportunities for individualized treatment among patients with complex allergic conditions and elevated IgE levels.
However, further research is needed to establish optimal dosing strategies, evaluate long-term safety, and determine whether improvements in clinical and patient-reported outcomes translate into measurable health care utilization and economic benefits.

Reference

Lo Scalzo L, Galletta F, Cafarotti A, et al. Real-life lessons on omalizumab and food allergy: The potential for unexplored outcomes. World Allergy Organ J. 2026;19(5):101390. doi: 10.1016/j.waojou.2026.101390